GILD

Gilead Sciences
D

GILD

105.940
USD
2.58
(2.50%)
مغلق
حجم التداول
377,996
الربح لكل سهم
7
العائد الربحي
2.98
P/E
1,176
حجم السوق
132,029,404,891
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 3 أشهر
    buy
    2024-10-30 14:50
    GILD Chart
    المزيد
أصول ذات صلة
    ABBV
    ABBV
    0.400
    (0.21%)
    193.450 USD
    AMGN
    AMGN
    1.75
    (0.59%)
    296.86 USD
    BIIB
    BIIB
    4.870
    (3.65%)
    138.390 USD
    BMY
    BMY
    -0.185
    (-0.33%)
    55.960 USD
    GSK
    GSK
    0.410
    (1.13%)
    36.560 USD
    JNJ
    JNJ
    2.040
    (1.31%)
    157.280 USD
    MRK
    MRK
    -1.240
    (-1.45%)
    84.440 USD
    PFE
    PFE
    0.180
    (0.71%)
    25.640 USD
    REGN
    REGN
    10.02
    (1.51%)
    673.66 USD
    المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).